Supplementary Financial Materials I 2Q Results Fiscal 2026 2Q Results & Outlook

Summary of Performance

For 2Q of this fiscal year, consolidated net sales were 57.6 hundred million yen, an increase of +12.1% year-over-year, recording the highest first-half on record. Operating income was 6.8 hundred million yen, up +14.5% year-over-year. Gross profit margin was 30.5%, roughly in line with the prior year. By segment, demand expansion in Laboratory, Industry and Medical contributed. Efforts continue to absorb cost fluctuations caused by Middle East conditions through surcharges and other measures. Full-year outlook has been revised upward to net sales of 120,870 million yen and operating income of 13,750 million yen.

Outlook and Impact for Investors

With solid R&D investment and AI-related investment in the first half, the Laboratory and Industry divisions are expected to remain firm in the second half. The Medical division is conservatively forecasted due to revisions to medical fee schedules, but improvement is anticipated. Attention is required regarding raw material cost fluctuations from Middle East conditions; however, gross margin is expected to stabilize through cost updates and expansion of proprietary products. Costs related to rental and calibration centers are progressing as planned.